BMO Capital analyst Evan David Seigerman reiterated a Market Perform rating and $147.00 price target on Neurocrine Bio. (NASDAQ: NBIX).The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE